AGS 6MF
Alternative Names: AGS6MFLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Agensys
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA (Parenteral, Injection)
- 10 May 2010 Phase-I clinical trials in Cancer in USA (Parenteral)